Page 48 - AN-2-3
P. 48

Advanced Neurology                                                        TRPM7 signaling in glioblastoma



            with a Superdex 16/60 75 columns (GE Healthcare, USA)   protein concentration in the centrifuged supernatant was
            with buffer (20 mM Tris, pH  8.0, 200 mM NaCl, 2 mM   measured with Pierce BCA Protein Assay Kit (Thermo
            2-mercaptoethanol). Samples containing proteins of desired   Fisher Scientific, USA). Samples were boiled and 40  µg
            molecular weight validated by SDS-PAGE were concentrated   protein was loaded into each well of the SDS-PAGE gel. The
            and quantified using NanoDrop (Thermo Fisher Scientific,   gel was transferred to a 0.2 µm PVDF membrane (Bio-Rad,
            USA). The quality of the final protein product was evaluated   USA) and blocked using 5% skim milk. Membranes were
            by mass spectrometry.                              incubated in the appropriate primary antibodies overnight
                                                               at 4°C: anti-TRPM7 (1:1000, ab85016, Abcam, UK); anti-
            2.5. Pull-down assay                               calcineurin A (1:500, G182-1847; BD Pharmingen, CA);
            The pull-down assay was performed using HisPur cobalt   anti-phospho-AKT (1:1000, 9271S, CST, USA); anti-AKT
            beads according to the manufacturer’s instructions (Thermo   (1:1000, 2920S, CST, USA); anti-phospho-ERK (1:1000,
            Fisher Scientific, USA). In brief, cells were lysed using   5726S, CST, USA); anti-ERK (1:1000, 4695S, CST, USA);
            pull-down lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM   anti-GAPDH (1:5000, 2118S, CST, USA); anti-6×His
            NaCl, 1% NP-40, 0.25% sodium deoxycholate, and protease   (1:1000, Y1010, UBPBio, USA). Following incubation with
            inhibitors), and the lysate was incubated with the 6×His-  the respective mouse (1:7500, 7076S, CST, USA) or rabbit
            calmodulin on a rotator at 4°C overnight. HisPur cobalt   (1:10000, 7074S, CST, USA) secondary antibodies, protein
            beads were incubated with the pull-down mixture, washed   signals were detected using X-ray film (Clonex, CA) after
            three times with lysis buffer, and eluted with pull-down   incubating blots in enhanced chemiluminescence reagents
            lysis buffer containing 150 mM imidazole. All samples were   (Bio-Rad, USA). The intensity of each protein band was
            subsequently analyzed using Western blot.          analyzed using ImageJ.

            2.6. Cell viability assay                          2.9. Wound healing migration assay
            U251 cells were seeded at 3×10  cells/well in 96-well plates   A vertical wound was created on the U251 cell layer in
                                     3
            and incubated in a medium containing 10 – 80 µM CsA.   12-well plates. Culture medium containing 1% FBS and
            After 24  h, the Cell Counting Kit-8 (CCK-8, Dojindo,   drug treatments were added to corresponding wells. Four
            Japan) solution was added and incubated for 3  h. The   representative images at marked locations along the wound
            absorbance at 450 nm was determined using a microplate   were captured per well using a phase-contrast Olympus
            reader (Synergy H1, Biotek, USA).                  microscope (×10 objective, CKX41)  at 0 and 24  h after
                                                               treatment. The images were analyzed using ImageJ and the
            2.7. Quantitative reverse transcription PCR        following formula: Percentage of closure = Gap(T  – T )/
            (qRT-PCR)                                          GapT  ×100%.                            24  0

            Total RNA was extracted using the PureLink RNA Mini    0
            Kit (Thermo Fisher Scientific, USA) and quantified using   2.10. Oris migration assay
            Nanodrop (Thermo Fisher Scientific, USA). High-Capacity   The Oris migration assay was performed according to the
            cDNA Reverse Transcription Kit (Applied Biosystems,   manufacturer’s instructions (Platypus Technologies, USA).
            USA) was used to synthesize cDNA. cDNA was then    In brief, U251 cells were seeded into the Oris 96-well plate
            amplified with TRPM7 and GAPDH primers using       at 2.5 × 10   cells/mL and a circular wound was created
                                                                        4
            Platinum SYBR Green qPCR SuperMix-UDG with ROX     in each well after the removal of the stoppers. A culture
            (Thermo Fisher Scientific, USA) in the 7900HT Fast Real-  medium containing 1% FBS and drug treatments were
            Time PCR System (Applied Biosystems, USA). TRPM7   added to each well. An image was taken for each well using
            RT-qPCR   primers:  CCAGAAACCAAGCGCTTTCC           a phase-contrast  Olympus  microscope  (×4  objective)  at
            (forward); GCCATGACCTGCCTCTTCAT (reverse).         0-, 12-, 24-, and 48-h post-treatment. The percentage of
            GAPDH     primers:  ACTCCACTCACGGCAAATTC           closure was analyzed in the same fashion as the wound
            (forward);      CCAGTAGACTCCACGGACATACT            healing assay.
            (reverse). The quantity mean of TRPM7 in each sample was
            calculated by SDS Software v2.4 (Thermo Fisher Scientific,   2.11. Cell invasion assay
            USA) and normalized to the reference gene, GAPDH.  The Corning BioCoat Matrigel invasion assay was
                                                               conducted  according  to  the  manufacturer’s  instructions
            2.8. Western blot                                  (Corning, USA). In summary, U251  cells were seeded
            Cells  were  resuspended in  RIPA  buffer  (20 mM  Tris-  into the 24-well Matrigel chambers at 5 × 10  cells/mL in
                                                                                                   4
            HCl, pH  7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium   serum-free DMEM and placed into the companion plate
            deoxycholate, 0.1% SDS, protease inhibitors) and the   containing a chemoattractant (DMEM with 10% FBS).


            Volume 2 Issue 3 (2023)                         3                          https://doi.org/10.36922/an.334
   43   44   45   46   47   48   49   50   51   52   53